Evidence map›Paper›PMID 36313630›Full record

ArticleFrontiers in oncology2022

A framework for identification and classification of liver diseases based on machine learning algorithms.

Huanfei Ding, Muhammad Fawad, Xiaolin Xu, Bowen Hu

Abstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Huanfei DingThe First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Muhammad FawadSchool of Public Health and Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Xiaolin XuSchool of Public Health and Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Bowen HuThe First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is one of the most commonly seen liver disease. Most of HCC patients are diagnosed as Hepatitis B related cirrhosis simultaneously, especially in Asian countries. HCC is the fifth most common cancer and the second most common cause of cancer-related death in the World. HCC incidence rates have been rising in the past 3 decades, and it is expected to be doubled by 2030, if there is no effective means for its early diagnosis and management. The improvement of patient's care, research, and policy is significantly based on accurate medical diagnosis, especially for malignant tumor patients. However, sometimes it is really difficult to get access to advanced and expensive diagnostic tools such as computed tomography (CT), magnetic resonance imaging (MRI) and positron emission tomography (PET-CT)., especially for people who resides in poverty-stricken area. Therefore, experts are searching for a framework for predicting of early liver diseases based on basic and simple examinations such as biochemical and routine blood tests, which are easily accessible all around the World. Disease identification and classification has been significantly enhanced by using artificial intelligence (AI) and machine learning (ML) in conjunction with clinical data. The goal of this research is to extract the most significant risk factors or clinical parameters for liver diseases in 525 patients based on clinical experience using machine learning algorithms, such as regularized regression (RR), logistic regression (LR), random forest (RF), decision tree (DT), and extreme gradient boosting (XGBoost). The results showed that RF classier had the best performance (accuracy = 0.762, recall = 0.843, F1-score = 0.775, and AUC = 0.999) among the five ML algorithms. And the important orders of 14 significant risk factors are as follows: Total bilirubin, gamma-glutamyl transferase (GGT), direct bilirubin, hemoglobin, age, platelet, alkaline phosphatase (ALP), aspartate transaminase (AST), creatinine, alanine aminotransferase (ALT), cholesterol, albumin, urea nitrogen, and white blood cells. ML classifiers might aid medical organizations in the early detection and classification of liver disease, which would be beneficial in low-income regions, and the relevance of risk factors would be helpful in the prevention and treatment of liver disease patients.

Indexed as

artificial intelligenceclassificationhepatitis B cirrhosishepatocellular carcinomaliver disease

Identifiers

PMID36313630
PMCPMC9614094

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.